OTC Monograph Process Not Broken But Needs Repair – CHPA
This article was originally published in The Tan Sheet
The trade group’s presentation at FDA’s upcoming public hearing will underscore the monograph process’s value in making more OTC drugs available but also ask why the process is not working as intended. Scheduled speakers also include Peter Barton Hutt, the former FDA chief counsel recognized as the architect of the monograph system, and self-care medication expert Bill Soller.
You may also be interested in...
Decision, explained by Principal Deputy Commissioner Woodcock, turns page on FDA’s 2019 announcement, after hemp was de-scheduled in 2018 farm bill, it would consider rulemaking for lawful use of hemp in supplements.
Former acting commissioner Stephen Ostroff and Sharon Lindan Mayl, previously a senior advisor to FDA commissioner on food programs, say Reagan-Udall report was accurate in finding that establishing food program leadership with defined authorities is key to improving the programs, which include regulation of supplement manufacturing and marketing.
“Right now, it looks like [FDA’s] hands are tied because that's their message … But they're holding both ends of the rope. Come on, get that knot undone,” says AHPA president Michael McGuffin. “To anybody who's looking at this as an outsider, you would say, ‘What is the agency doing?’’ says NPA CEO Daniel Fabricant.